Literature DB >> 33922370

Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.

Anthony Torres-Ruesta1,2, Rhonda Sin-Ling Chee1, Lisa F P Ng1,2,3.   

Abstract

Alphaviruses are mosquito-borne pathogens distributed worldwide in tropical and temperate areas causing a wide range of symptoms ranging from inflammatory arthritis-like manifestations to the induction of encephalitis in humans. Historically, large outbreaks in susceptible populations have been recorded followed by the development of protective long-lasting antibody responses suggesting a potential advantageous role for a vaccine. Although the current understanding of alphavirus antibody-mediated immunity has been mainly gathered in natural and experimental settings of chikungunya virus (CHIKV) infection, little is known about the humoral responses triggered by other emerging alphaviruses. This knowledge is needed to improve serology-based diagnostic tests and the development of highly effective cross-protective vaccines. Here, we review the role of antibody-mediated immunity upon arthritogenic and neurotropic alphavirus infections, and the current research efforts for the development of vaccines as a tool to control future alphavirus outbreaks.

Entities:  

Keywords:  alphavirus; alphavirus vaccine; antibody; immunity

Year:  2021        PMID: 33922370     DOI: 10.3390/microorganisms9050899

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  218 in total

1.  Functional characterization of the Sindbis virus E2 glycoprotein by transposon linker-insertion mutagenesis.

Authors:  Chanakha K Navaratnarajah; Richard J Kuhn
Journal:  Virology       Date:  2007-02-15       Impact factor: 3.616

2.  Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice.

Authors:  Mohsin Khan; Rekha Dhanwani; Putcha Venkata Lakshamana Rao; Manmohan Parida
Journal:  Virus Res       Date:  2012-05-17       Impact factor: 3.303

3.  Estimating the burden of disease and the economic cost attributable to chikungunya, Andhra Pradesh, India, 2005-2006.

Authors:  T Seyler; Y Hutin; V Ramanchandran; R Ramakrishnan; P Manickam; M Murhekar
Journal:  Trans R Soc Trop Med Hyg       Date:  2009-08-25       Impact factor: 2.184

4.  Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice.

Authors:  M K Hart; W Pratt; F Panelo; R Tammariello; M Dertzbaugh
Journal:  Vaccine       Date:  1997-03       Impact factor: 3.641

5.  Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients.

Authors:  Gianandrea Borgherini; Patrice Poubeau; Frederik Staikowsky; Manuella Lory; Nathalie Le Moullec; Jean Philippe Becquart; Catherine Wengling; Alain Michault; Fabrice Paganin
Journal:  Clin Infect Dis       Date:  2007-04-18       Impact factor: 9.079

6.  Chimeric alphavirus vaccine candidates for chikungunya.

Authors:  Eryu Wang; Eugenia Volkova; A Paige Adams; Naomi Forrester; Shu-Yuan Xiao; Ilya Frolov; Scott C Weaver
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

Review 7.  Arthritogenic alphaviruses--an overview.

Authors:  Andreas Suhrbier; Marie-Christine Jaffar-Bandjee; Philippe Gasque
Journal:  Nat Rev Rheumatol       Date:  2012-05-08       Impact factor: 20.543

8.  Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate.

Authors:  Yi-Hao Chan; Teck-Hui Teo; Age Utt; Jeslin Jl Tan; Siti Naqiah Amrun; Farhana Abu Bakar; Wearn-Xin Yee; Etienne Becht; Cheryl Yi-Pin Lee; Bernett Lee; Ravisankar Rajarethinam; Evan Newell; Andres Merits; Guillaume Carissimo; Fok-Moon Lum; Lisa Fp Ng
Journal:  EMBO Mol Med       Date:  2019-06       Impact factor: 12.137

9.  ACTIVE IMMUNIZATION OF GUINEA PIGS WITH THE VIRUS OF EQUINE ENCEPHALOMYELITIS : III. QUANTITATIVE STUDIES OF SERUM ANTIVIRAL BODIES IN ANIMALS IMMUNIZED WITH ACTIVE AND INACTIVE VIRUS.

Authors:  H R Cox; P K Olitsky
Journal:  J Exp Med       Date:  1936-07-31       Impact factor: 14.307

10.  Prophylaxis and therapy for Chikungunya virus infection.

Authors:  Thérèse Couderc; Nassirah Khandoudi; Marc Grandadam; Catherine Visse; Nicolas Gangneux; Sébastien Bagot; Jean-François Prost; Marc Lecuit
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

View more
  1 in total

1.  A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections.

Authors:  Christin Schmidt; Erik Haefner; Julia Gerbeth; Tim Beissert; Ugur Sahin; Mario Perkovic; Barbara S Schnierle
Journal:  Mol Ther Nucleic Acids       Date:  2022-05-02       Impact factor: 10.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.